Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?

Isla S. Mackenzie; Thomas M. MacDonald

doi:10.1093/eurheartj/ehac415

Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?

Isla S. Mackenzie
, Thomas M. MacDonald (Lead / Corresponding author)

Research output: Contribution to journal › Editorial › peer-review

2 Citations (Scopus)

Abstract

This editorial refers to ‘Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial’, by W. Doehner et al., https://doi.org/10.1093/eurheartj/ehac320.

Original language	English
Pages (from-to)	3447-3449
Number of pages	3
Journal	European Heart Journal
Volume	43
Issue number	36
Early online date	8 Aug 2022
DOIs	https://doi.org/10.1093/eurheartj/ehac415
Publication status	Published - 21 Sept 2022

Access to Document

10.1093/eurheartj/ehac415

Cite this

@article{d50b1b1640c2478b8a0bf09305b6e3d8,

title = "Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?",

abstract = "This editorial refers to {\textquoteleft}Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial{\textquoteright}, by W. Doehner et al., https://doi.org/10.1093/eurheartj/ehac320.",

author = "Mackenzie, \{Isla S.\} and MacDonald, \{Thomas M.\}",

note = "Publisher Copyright: {\textcopyright} TheAuthor(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: [email protected].",

year = "2022",

month = sep,

day = "21",

doi = "10.1093/eurheartj/ehac415",

language = "English",

volume = "43",

pages = "3447--3449",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "36",

}

TY - JOUR

T1 - Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction

T2 - a sweet added benefit?

AU - Mackenzie, Isla S.

AU - MacDonald, Thomas M.

PY - 2022/9/21

Y1 - 2022/9/21

N2 - This editorial refers to ‘Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial’, by W. Doehner et al., https://doi.org/10.1093/eurheartj/ehac320.

AB - This editorial refers to ‘Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial’, by W. Doehner et al., https://doi.org/10.1093/eurheartj/ehac320.

UR - https://www.scopus.com/pages/publications/85138247547

U2 - 10.1093/eurheartj/ehac415

DO - 10.1093/eurheartj/ehac415

M3 - Editorial

C2 - 35938377

SN - 0195-668X

VL - 43

SP - 3447

EP - 3449

JO - European Heart Journal

JF - European Heart Journal

IS - 36

ER -

Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this